Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 15;615(7954):920–924. doi: 10.1038/s41586-023-05812-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — Example from a 71-year-old patient with KMT2Ar AML relapsed after an allogeneic stem cell transplant, who received revumenib at 339 mg PO q12h (Arm A), and achieved CRh, MRD negative remission. Differentiation syndrome manifested as chest pain with a small pericardial effusion, and a possible prodrome of neck pain likely related to expansion of cervical nodes, all resolved promptly with initiation of steroids followed by tapering doses. Hydroxyurea was used to control leukocytosis. AML, acute myeloid leukaemia; ANC, absolute neutrophil count; CRh, complete remission with partial haematologic recovery; MRD, minimal or measurable residual disease; PB, peripheral blood; PO, by mouth; q12h, every 12 h; WBC, white blood cell.